Judith Seidman

Work with the Government of Canada to bolster and create pan-Canadian standardized health data and digital tools to better track and have an up-to-date picture of diabetes and it's evolving impacts. Increase funds for diabetes in the Federal Budget specifically to increase funds directed to the Canadian Diabetes Strategy to reflect growth in diabetes prevalence and cost. Increase Federal funding for Diabetes Research - work directed towards increasing funding to federal granting councils, in particular the Canadian Institutes of Health Research (CIHR) through the Federal Budget. Funding for Implementation of the Framework for Diabetes tabled by the Minister of Health on October 5, 2022.

Increase funds for diabetes in the Federal Budget specifically to increase funds directed to the Framework for Diabetes in Canada its components and a strategy to reflect growth in diabetes prevalence and cost. Bill C-64 - An Act Respecting Pharmacare Increase Federal funding for Diabetes Research - work directed towards increasing funding to federal granting councils, in particular CIHR through the Federal Budget. Aboriginal Diabetes Initiative - work towards making funding for this Initiative permanent. (Previous work directed towards continuation of funding beyond 2010).

Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Agency for Drugs and Technologies in Health (CADTH)/Common Drug Review as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance. National Strategy for Drugs for Rare Disease as it relates to separate regulatory pathways for drugs for rare diseases and the government strategy. Monitoring and engaging the Government and Parliamentarians on policies and programs that would provide greater clarity and predictability in the tax outcomes and improvements to tax measures such as the Manufacturing & Processing (M&P) credit and the Scientific Research & Developmental (SR&ED). Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework. Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries Policies related to the National Strategy for Drugs for Rare Disease as it relates to separate regulatory pathway for drugs for rare diseases and the government strategy. Policies related to Subsequent Entry Biologics (SEBs) pertaining to Draft Guidance for Sponsors; Information and Submission requirements for SEBs, regulations and intellectual property policies, naming conventions Monitoring and engaging on the Government’s commitment (Budget, SFT, Fall Economic Update) to create a national strategy for drugs for rare diseases; create a new Canadian Drug Agency; and the implementation of national, universal pharmacare. Pharmaceutical policy and any negotiations of a Health Accord or agreement with the Provinces/Territories, as it relates to National Pharmacare/universal or catastrophic drug coverage, Drug policies & Pricing. The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy. Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's biomanufacturing and life sciences sector strategy National Pharmacare (Bill C-64, An Act respecting pharmacare) Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies. Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products. Income Tax Act as it relates to biopharmaceutical industry. Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy. Discussions around the World Trade Organization consideration of a TRIPS Patent Waiver - Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". The Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of importation legislation in the United States. Standing Committee on Finance (FINA) as it relates to pre-budget consultations. Pharmaceutical intellectual property protection as it relates to international trade agreements Patent Act and Patented Medicines (Notice of Compliance) Regulations, as it relates to the regulation of intellectual property, approval for therapeutic products, changes to modernize the Right of Appeal House of Commons Standing Committee of Science and Research (SRSR) as it relates to Science in Canada and/or any other pertinent legislative proposal before the committee House of Commons Standing Committee of Industry and Technology (INDU) as it

YOUNG TRAINEES AND STUDENTS: Advocate for continued support of and investment in the next generation of highly skilled researchers through the federal awards system for doctoral students, post-doctoral trainees and fellows. RESEARCH HOSPITALS: Advocate for direct support and stability for Canada's academic health science centres and research hospitals that will further enable them to fulfill their strategically critical contribution to Canada's health and economic security. INDUSTRY: Advocate for policies that enhance the health and biosciences sector’s capacity to do business in Canada and to invest in Canadian health research and commercialization. INDIRECT COSTS OF RESEARCH: Advocate for an increase to the minimum threshold for reimbursement of indirect research costs for all institutions via the Research Support Fund. INDIGENOUS RESEARCH: Advocate for greater investments in Indigenous health research through the three granting councils and the Canada Research Coordinating Committee. HEALTH RESEARCH: Focus on increasing public investments across the research spectrum of operating grants, people and infrastructure and encourages investments from private and private-not-for-profit sectors. GOVERNMENT FUNDING: Advocate for increased health research funding through the three granting councils (Canadian Institutes of Health Research, Social Sciences and Humanities Research Council, and Natural Sciences and Engineering Research Council of Canada) and the Canada Research Coordinating Committee. FEDERAL BUDGET CONSULTATION: Advocate for continued support of Canadian health research and health innovation through investments and commitments made in the federal budget, such as the Strategic Science Fund, the Canada Graduate Scholarship Program, etc. DIVERSE TALENT BASE: Advocate for better support for a diversified talent base in Canada, with a focus on Indigenous researchers, Black and people of colour researchers, early-career researchers, and other underrepresented and equity-deserving groups. DIGITAL HEALTH SYSTEM: Advocate for investment in the digitalization of our health system so that high-quality data and digital technologies support healthcare decisions, empower patients as partners, and drive research and innovation.

Advocacy regarding pending CRTC review of Wireless Code Replacement Worker Legislation - TELUS is interested in legislation that bans replacement workers during a labour dispute as it would hinder our ability to operate and provide ongoing service to customers. Providing input to the government for development of an anti-fraud strategy to create an integrated fraud takedown framework. Discussions regarding federal support for science and research talent development, with a focus on creating public-private partnerships that enhance education and training opportunities. These efforts aim to advance social good by increasing the participation of women and marginalized groups in the digital economy and STEM sectors. Developing protocols for Canada’s Greenhouse Gas Offset Credit System Advocacy for potential amendments to the Copyright Act, with respect to updating unclear regulation of Internet Service Providers. Advocacy regarding fibre-to-the-premises wholesale access; including discussions about TELUS' expansion and extended offerings. Advocacy regarding improving resilience and redundancy in TELUS’ network, including the potential to expand remote network connectivity and build out critical infrastructure in the North. Communicating with the government about how to support adopting digital tools in the agriculture sector. Advocacy concerning the development and implementation of national artificial intelligence policies, including but not limited to the Sovereign AI Compute Strategy and the AI Compute Access Fund. Informing officials about TELUS' plans to monetize passive infrastructure. Informing Federal officials about the risks posed by copper theft to public safety and telecommunications infrastructure, and advocating for enhanced collaboration between governments (provincial and federal) and industry to address this growing issue effectively. Advocating for stricter regulations around theft and damage of telecommunications infrastructure through Bill C-26: An Act respecting cyber security, amending the Telecommunications Act and making consequential amendments to other Acts. Review of the Personal Information Protection and Electronic Documents Act (PIPEDA) as relates to communications and data service providers’ obligations Regulatory environment affecting the Canadian wireless market, including regulatory framework with regard to the requirements around rural network infrastructure builds, the policy framework around spectrum auction rules and regulations on the purchase of existing Canadian wireless companies. Potential Amendments to the Broadcasting and Telecommunication Acts, with respect to streamlining regulation of the broadcasting and telecommunication industry. Policy framework with respect to the relationship between digital/wireless connectivity and climate policy. Policy Framework with regard to the terms and conditions of auction for Spectrum Licences Informing Federal officials around TELUS initiatives in the Health Care field and communicating the need for increased cooperation in developing next generation health care services between all levels of Government. Critical infrastructure and cyber security - protection of facilities, networks, technology, assets and systems. Canadian Radio-television and Telecommunications Commission review of Basic Telecommunications Services Broadcasting Policies Relating to Specialty Television Broadcasting Policies Relating to Conventional Television Broadband Canada – Connect to Innovate program which is of interest to TELUS, with respect to advancing rural and remote network connectivity in Canada. Bills related to lawful access obligations that will have a direct impact on the Company from a financial and operational perspective, as well as impact on TELUS customers from a privacy perspective, and with respect to obligations imposed on carriers with respect to intercept and subscriber information. As a supplier to the Government of Canada, TELUS regularly engages in di

Engage with government to raise awareness on copper theft and advance policy solutions. Spectrum policy framework as related to incumbent wireless carriers with respect to all technological and financial implications of proposed government policies. Review of the Personal Information Protection and Electronic Documents Act (PIPEDA) as relates to communications service providers’ obligations Replacement Worker Legislation - TELUS is interested in legislation that bans replacement workers during a labour dispute as it would hinder our ability to operate our organization and serve our customers. Regulatory environment affecting the Canadian wireless market, including regulatory framework with regard to the requirements around rural network infrastructure builds, the policy framework around spectrum auction rules and regulations on the purchase of existing Canadian wireless companies. Proposed Digital Economy Strategies with respect to spectrum and environmental policy. Potential Amendments to the Broadcasting and Telecommunication Acts, with respect to streamlining regulation of the broadcasting and telecommunication industry. Policy framework with respect to the relationship between digital/wireless connectivity and climate policy. Policy Framework with regard to the terms and conditions of auction for Spectrum Licenses. Inviting MPs to Kits for Kids, an event during which the client will donate backpacks and supplies to schools and community groups across Canada. Informing Federal officials around TELUS initiatives in the Health Care field and communicating the need for increased cooperation in developing next generation health care services between all levels of Government. Critical infrastructure and cybersecurity - protection of facilities, networks, technology, assets and systems. Copyright regulations and the Copyright Modernization Act with respect to the scheduled five year review. Communicating with the government about adopting digital tools in the agriculture sector. Canadian Radio-television and Telecommunications Commission review of Basic Telecommunications Services Broadcasting Policies Relating to Specialty Television Broadcasting Policies Relating to Conventional Television Broadband Canada – Connect to Innovate program which is of interest to TELUS, with respect to advancing rural and remote network connectivity in Canada. Bills related to lawful access obligations that will have a direct impact on the Company from a financial and operational perspective, as well as impact on TELUS customers from a privacy perspective, and with respect to obligations imposed on carriers with respect to intercept and subscriber information. As a supplier to the Government of Canada, TELUS regularly engages in discussions related approaches to reduce costs in the procurement of end-user devices, networks and associated support services and solutions.

Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada. Communication regarding free trade agreements as they relate to the biopharmaceutical industry. The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors. Public Health Agency of Canada, regarding the federal response to the hepatitis C virus. Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada. Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages. Communications with Heath Canada regarding modernization of the medical devices regulatory framework. Communications with Health Canada regarding the evolution of the regulatory framework to address advanced therapeutic products. Communications with Health Canada regarding the application of its nitrosamine guidelines. Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials. Communications with Health Canada regarding guidelines for pediatric action plans. Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors. Communications regarding the design and implementation of the federal Drugs for Rare Diseases strategy. Communications regarding national pharmacare legislation, regulations, policies or programs. Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime. Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices. Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.

Policies or Program • Connect with government officials to discuss opportunities to support Canada's health care system and to improve seniors care in Canada. Grant, Contribution or Other Financial Benefit • To advocate for future budgetary funding for the Canadian Association for Long Term Care, including funding for health human resources and long-term care infrastructure support, as well as funding and other supports for COVID-19 related challenges.

Capital equipment (CT and MRI): Guide a dedicated investment of $2 billion over three years for radiology equipment to improve access to modern medical imaging equipment. Streamline the process for equipment installation and reduce the substantial associated labour costs. Clinical decision support: Support the national integration of Clinical Decision Support (CDS) systems into electronic medical records (EMRs) to ensure that patients receive the right test at the right time. Health human resources: Develop a strategy to recruit and retain radiologists, medical radiation technologists, and sonographers as part of a national approach to health human resources to reduce backlogs and improve health services. Federal Budget - investment in First Nations communities for medical imaging equipment and access to radiologists to improve care for population Artificial Intelligence: Demonstrate leadership in AI by providing financial support for the Health Artificial Intelligence Validation Network (HAIVN) to improve the evaluation and regulation of AI in Canada as part of Health Canada’s Medical Devices Directorate regulatory process, for the purpose of improved healthcare, economic development and innovation in Canada.

CYBER SECURITY - Encourage the government to invest in cybersecurity innovation, talent, and infrastructure; modernize research and development; accelerate commercialization in the space; support the secure digitalization of small-and-medium-sized enterprises (SMEs); and improve the global competitiveness of Canada’s cybersecurity industry. ARTIFICIAL INTELLIGENCE - Advocate for future-proofed, globally competitive, and interoperable policies that position artificial intelligence as a positive economic driver, and support the responsible development, deployment, and use of AI in business. PRIVACY AND ACCESS TO INFORMATION - Ensure that the modernization of Canada’s privacy legislation strikes the right balance between protecting consumers and promoting the ability of firms to innovate and compete by responsibly and securely using data. HOUSING - Support policies that enable the creation of more housing supply, incentivize investment in residential construction, and restore housing affordability for Canadian families. NATIONAL SECURITY/ECONOMIC SECURITY - Advancing policies related to enhancing Canada’s economic and national security. Key priorities include strengthening economic resilience, prudently navigating geopolitical challenges to trade and international relations, safeguarding business operations against new and emerging threats, and fostering conditions for economic growth. TRANSPORTATION - Regarding the consistent funding of trade-enabling infrastructure projects; the development of a competitive and efficient transportation network including all modes of transportation. TELECOMMUNICATIONS - Creating the right investment incentives to foster vibrant competition in the sector as a whole; responding to decisions regarding third-party access that will impact the deployment of internet services in rural and remote communities; and responding to regulatory proposals re: cell phone pricing. TAXATION AND FINANCE – With regard to undertaking a comprehensive and independent tax system review. TAXATION AND FINANCE – With regard to the measurement and improvement of Canada’s tax competitiveness, including: reforming the taxation, remittance, filing and audit processes of Canadian businesses; removing tax barriers for childcare expenses; addressing the taxation of family business transfers; and mobilizing private capital for recovery and growth. TAXATION AND FINANCE - With regard to modernizing our financial systems through open banking and digital currencies TAXATION AND FINANCE - Responding to proposals addressing taxation of digital services. TAXATION AND FINANCE - Maintaining and expanding real-time data made freely available to Canadian businesses, municipalities, academic researchers, and community groups. SMALL BUSINESS – Legislation, regulations and support programs that give Canadian small and medium-sized enterprises (SMEs) the tools to grow in Canada and internationally, including reducing their red tape and compliance burden. PRIVACY AND ACCESS TO INFORMATION - Improving digital privacy legislation to meet the needs of industry. PENSIONS - Treatment of corporate pensions in the event of bankruptcy. NATURAL RESOURCES - Support for the adoption of policy recommendations to strengthen Canada’s world-leading position in the mining industry, oil and gas, and forestry products. OPEN DATA - Maintaining and expanding real-time data made freely available to Canadian businesses, municipalities, academic researchers, and community groups. LABOUR: Ensuring that any changes to the Canada Labour Code are implemented in response to defined and demonstrated issues and not to increase regulatory burdens for employers. INTERNATIONAL TRADE – With respect to issues relating to import and export controls INTERNATIONAL TRADE - Negotiating bilateral, regional, and multilateral trade agreements and promoting them to Canadian businesses. INTERNATIONAL TRADE - Improving federal laws and regulations pertaining to responsible business conduct r

Advocate for changes to facilitate adoption of auto features for retirement savings. Advocate for legislative or regulatory changes to allow for automatic features in workplace pension plans. Discussions related to the implementation of CRA Notice 344 Consultation on the National Strategy on mental health of men and boys Discussions related to Bill S-5 Connected Care for Canadians Act. FCAC direction to update complaint-handling information for insurers Discussions related to drug pricing, including decisions, policies and processes of the Patented Medicine Prices Review Board (PMPRB) Discussions related to supply and shortages of drugs in Canada, including the Multi-Stakeholder Steering Committee. Discussions related to regulatory burden, including “cutting red tape”. Impacts on Canadian insurers of proposed U.S. tax measures. Discussions relating to the efficiency and effectiveness of the financial sector regulatory system as it pertains to insurance companies. Discussing plans on the Data Collection Modernization initiative Promotion of a broader range of investments by insurance companies (e.g., farmland, timberland, fintechs) Statutory review of the Insurance Companies Act as it relates to insurance products and investments. Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing. Promotion of pension products, including decumulation solutions. Discussions related to the implementation of the Interpretation letter on the Canada health act related to physician equivalent services. Inter-provincial harmonization and trade barriers as it relates to insurance products. Discussions related to the financial sector policy review. Office of the Superintendent of Financial Institutions (OSFI). Guidelines related to risk management, capital and accounting for insurance companies. This includes capital charges for infrastructure investments under the LICAT. International Trade with respect to opening trade relations, regulations, foreign ownership and national treatment in foreign markets, with regards to India, Europe, China, Japan, Trans-Pacific partnership (TPP), Canada-United States-Mexico Agreement (CUSMA), Plurilateral Trade In Services Agreement (TISA) and the World Trade Organization (WTO). Work to ensure that the income tax act does not put insurance companies at a competitive disadvantage. Promotion of risk-based and principles-based regulation for financial institutions regulations. Personal Information Protection and Electronic Documents Act: seeking workable approaches to privacy rules affecting life and health insurers when the Act is updated. Income Tax Regulations (section 6(1)(f) as it relates to income tax withholding on wage loss replacement plans (disability income benefits). Income Tax Regulations, Part XIV. Income Tax Regulations, Part III: Updating income tax rules for life insurance policies. Income Tax Act, Section 146: Retirement income recommendations regarding the treatment of life insurance companies; Section 146.2 (TFSAs); Section 146.3 (RRIFs). Income Tax Act, Part VI as it relates to capital tax on financial institutions. Financing infrastructure projects, as it relates to investments by insurers Financial Transactions and Reports Analysis Centre of Canada (FINTRAC) risk-based guidance as it relates to life insurance Employment Insurance (EI) reform as it relates to disability benefits; and EI Premium Reduction Program issues. Amendments to Proceeds of Crime (Money Laundering) and Terrorist Financing rules as they affect insurance companies

Legislating Pharmacy Benefit Manager and Insurer practices in Canada US Tariffs on medication and other pharmacy products The implementation of pharmacare in Canada, with respect to the practice of pharmacy and the role of pharmacists in pharmacare The Cannabis Act, with respect to the medical cannabis regime and the role of pharmacists in dispensing and managing medical cannabis. Rural and remote student loan forgiveness expansion Regulation and complaint to the competition bureau regarding pharmacy benefit managers Proposed changes to the public service health care plan Federal investments to improve support for the pharmacy workforce Prescription drug cost containment strategies with respect to implications for the practice of pharmacy E-health specifically as it relates to the implementation of e-prescribing in Canada, including funding for Canada Infoway Prioritizing immigration of health care workers Health transfers: increased funding to Provinces and Territories for community health providers Working with Health Canada to implement measures to respond to national drug shortages, and responding to US proposals on importation Post-market surveillance of pharmaceutical products with respect to implications for the practice of pharmacy Foreign Credential recognition Program, Health Canada Health Human Resources (HHR) Strategy - working with the department to understand the entry of foreign-trained pharmacists to Canada First Nations and Inuit Health - Non-Insured Health Benefits program (NIHB) with respect to implications for the practice of pharmacy Emergency Preparedness/Pandemic Planning with respect to implications for the practice of pharmacy Funding for a Health Human Resources Strategy and mental health resources for health providers CONTROLLED DRUGS AND SUBSTANCES ACT: Amending the CDSA to add pharmacists as practitioners (Opioids)